Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Determinants of vitamin D levels in men receiving androgen deprivation therapy for prostate cancer.

Mennen-Winchell LJ, Grigoriev V, Alpert P, Dos Santos H, Tonstad S.

J Am Assoc Nurse Pract. 2015 Jan;27(1):39-47. doi: 10.1002/2327-6924.12122. Epub 2014 Apr 14.

PMID:
24729531
2.

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy.

Mennen-Winchell LJ, Grigoriev V, Alpert P, Dos Santos H, Tonstad S.

J Am Assoc Nurse Pract. 2014 Jan;26(1):40-8. doi: 10.1002/2327-6924.12066. Epub 2013 Aug 27.

PMID:
24170604
3.
4.

Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer.

Davison BJ, Wiens K, Cushing M.

Support Care Cancer. 2012 Oct;20(10):2287-94. doi: 10.1007/s00520-011-1331-5. Epub 2011 Dec 5.

PMID:
22138848
5.

Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.

Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE, Wake RW.

BJU Int. 2007 Nov;100(5):1060-5. Epub 2007 Sep 14.

6.

Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.

Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S.

Scand J Urol. 2014 Aug;48(4):350-5. doi: 10.3109/21681805.2014.884160. Epub 2014 Feb 19.

PMID:
24548220
7.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

8.

Quality of life in prostate cancer patients taking androgen deprivation therapy.

Dacal K, Sereika SM, Greenspan SL.

J Am Geriatr Soc. 2006 Jan;54(1):85-90.

PMID:
16420202
9.

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.

Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.

Urology. 2007 Jul;70(1):122-6.

PMID:
17656221
10.

Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.

Nadler M, Alibhai S, Catton P, Catton C, To MJ, Jones JM.

BJU Int. 2013 Jun;111(8):1301-9. doi: 10.1111/j.1464-410X.2012.11777.x. Epub 2013 Jan 25.

11.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

12.

Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.

Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.

Coll Antropol. 2008 Oct;32 Suppl 2:79-81.

PMID:
19138011
13.

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J.

PLoS Med. 2007 Mar;4(3):e103.

14.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
15.

Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

Shahinian VB, Kuo YF.

J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.

16.

Maintaining bone health in patients with prostate cancer.

Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR.

Med J Aust. 2006 Feb 20;184(4):176-9. Review.

PMID:
16489902
17.

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.

BJU Int. 2009 Nov;104(9):1208-14. doi: 10.1111/j.1464-410X.2009.08593.x. Epub 2009 Apr 17.

18.

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.

Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):237-43. doi: 10.1038/pcan.2011.71. Epub 2012 Jan 31.

PMID:
22289781
19.

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.

Can J Urol. 2007 Jun;14(3):3551-9.

PMID:
17594745
20.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

PMID:
21807761

Supplemental Content

Support Center